We serve Chemical Name:3-pyrrolidin-3-ylaniline,dihydrochloride CAS:1203681-66-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-pyrrolidin-3-ylaniline,dihydrochloride
CAS.NO:1203681-66-6
Synonyms:3-(Pyrrolidin-3-yl)aniline dihydrochloride;3-(PYRROLIDIN-3-YL)ANILINE 2HCL
Molecular Formula:C10H16Cl2N2
Molecular Weight:235.15300
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:38.05000
Exact Mass:234.06900
LogP:3.85970
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(Pyrrolidin-3-yl)aniline dihydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(PYRROLIDIN-3-YL)ANILINE 2HCL physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(PYRROLIDIN-3-YL)ANILINE 2HCL Use and application,3-(PYRROLIDIN-3-YL)ANILINE 2HCL technical grade,usp/ep/jp grade.
Related News: ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. Bis(3,3,4,4,5,5,6,6,6-nonafluorohexyl)sulfide manufacturers Soliris would need a “substantial discount” to reach a more appropriate price, according to its report. Using the widely leveraged measure for disease burden known as quality-adjusted life year (QALY), ICER calculated a range of $6,900 to achieve $50,000 per QALY to $25,700 to hit $200,000 per QALY. 4-benzoyl-3,4,5,6-tetrahydro-1H-benzo[f]quinolin-2-one suppliers A strategic CDMO partner who can uphold a strong product manufacturing approach can positively influence timeline, quality, and costs of bringing the drug to market. Cyclopropanecarboxamide, N-[2-(1,1-dimethylethyl)-1H-indol-5-yl]- vendor & factory So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off.,ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged.
